نتایج جستجو برای: anti vegf

تعداد نتایج: 383792  

Journal: :Molecular cancer therapeutics 2014
Dror Alishekevitz Rotem Bril David Loven Valeria Miller Tali Voloshin Svetlana Gingis-Velistki Ella Fremder Stefan J Scherer Yuval Shaked

We previously reported that the host response to certain chemotherapies can induce primary tumor regrowth, angiogenesis, and even metastases in mice, but the possible impact of anti-VEGF-A therapy in this context has not been fully explored. We, therefore, used combinations of anti-VEGF-A with chemotherapy on various tumor models in mice, including primary tumors, experimental lung metastases, ...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2012
D Y Heng M J Mackenzie U N Vaishampayan G A Bjarnason J J Knox M H Tan L Wood Y Wang C Kollmannsberger S North F Donskov B I Rini T K Choueiri

BACKGROUND A subset of patients treated with initial anti-vascular endothelial growth factor (VEGF) therapy exhibit progressive disease (PD) as the best response per RECIST criteria. METHODS Data from patients with metastatic renal cell carcinoma (mRCC) treated with anti-VEGF therapy were collected through the International mRCC Database Consortium from 12 centers. RESULTS One thousand and ...

Journal: :Nature Reviews Clinical Oncology 2011

Journal: :Nature Reviews Rheumatology 2010

Journal: :Nephrology Dialysis Transplantation 2007

2017
Thomas D. Gaddy Qianhui Wu Alyssa D. Arnheim Stacey D. Finley

Tumors exploit angiogenesis, the formation of new blood vessels from pre-existing vasculature, in order to obtain nutrients required for continued growth and proliferation. Targeting factors that regulate angiogenesis, including the potent promoter vascular endothelial growth factor (VEGF), is therefore an attractive strategy for inhibiting tumor growth. Computational modeling can be used to id...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2010
Anil Bagri Leanne Berry Bert Gunter Mallika Singh Ian Kasman Lisa A Damico Hong Xiang Maike Schmidt Germaine Fuh Beth Hollister Oliver Rosen Greg D Plowman

PURPOSE Inhibition of the vascular endothelial growth factor (VEGF) axis is the basis of all currently approved antiangiogenic therapies. In preclinical models, anti-VEGF blocking antibodies have shown broad efficacy that is dependent on both tumor context and treatment duration. We aimed to characterize this activity and to evaluate the effects of discontinuation of treatment on the dynamics o...

2010
Matthias Rinderknecht Alessandra Villa Kurt Ballmer-Hofer Dario Neri Michael Detmar

Vascular endothelial growth factor C (VEGF-C) is a key mediator of lymphangiogenesis, acting via its receptors VEGF-R2 and VEGF-R3. High expression of VEGF-C in tumors correlates with increased lymphatic vessel density, lymphatic vessel invasion, sentinel lymph node metastasis and poor prognosis. Recently, we found that in a chemically induced skin carcinoma model, increased VEGF-C drainage fro...

2013
Dror Alishekevitz Rotem Bril David Loven Valeria Miller Tali Voloshin Svetlana Gingis-Velistki Ella Fremder Stefan J. Scherer Yuval Shaked

We previously reported that the host response to certain chemotherapies can induce primary tumor regrowth, angiogenesis, and even metastases in mice, but the possible impact of anti–VEGF-A therapy in this context has not been fully explored.We, therefore, used combinations of anti–VEGF-Awith chemotherapy on various tumor models in mice, including primary tumors, experimental lungmetastases, and...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید